Loading...

Aratana Therapeutics

Nasdaq:PETX
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PETX
Nasdaq
$171M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • Aratana Therapeutics has significant price volatility in the past 3 months.
PETX Share Price and Events
7 Day Returns
-2.8%
NasdaqGM:PETX
-3.3%
US Pharmaceuticals
-0.3%
US Market
1 Year Returns
-30.8%
NasdaqGM:PETX
7.1%
US Pharmaceuticals
7%
US Market
PETX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aratana Therapeutics (PETX) -2.8% -4.6% -19.9% -30.8% -49.3% -74.7%
US Pharmaceuticals -3.3% -6% -2% 7.1% 5.1% 14.4%
US Market -0.3% 2% 8.5% 7% 37.7% 46.8%
1 Year Return vs Industry and Market
  • PETX underperformed the Pharmaceuticals industry which returned 7.1% over the past year.
  • PETX underperformed the Market in United States of America which returned 7% over the past year.
Price Volatility
PETX
Industry
5yr Volatility vs Market

Value

 Is Aratana Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Aratana Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Aratana Therapeutics.

NasdaqGM:PETX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:PETX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.67
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.674 (1 + (1- 21%) (0%))
0.782
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.8 * 5.96%)
7.5%

Discounted Cash Flow Calculation for NasdaqGM:PETX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Aratana Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGM:PETX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.5%)
2019 -20.00 Analyst x1 -18.60
2020 4.00 Analyst x1 3.46
2021 17.00 Analyst x1 13.69
2022 27.26 Est @ 60.33% 20.41
2023 38.99 Est @ 43.05% 27.16
2024 51.06 Est @ 30.95% 33.09
2025 62.54 Est @ 22.49% 37.70
2026 72.90 Est @ 16.56% 40.88
2027 81.95 Est @ 12.41% 42.75
2028 89.74 Est @ 9.51% 43.55
Present value of next 10 years cash flows $244.08
NasdaqGM:PETX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $89.74 × (1 + 2.73%) ÷ (7.5% – 2.73%)
$1,933.42
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $1,933.42 ÷ (1 + 7.5%)10
$938.26
NasdaqGM:PETX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $244.08 + $938.26
$1,182.34
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $1,182.34 / 48.97
$24.14
NasdaqGM:PETX Discount to Share Price
Calculation Result
Value per share (USD) From above. $24.14
Current discount Discount to share price of $3.50
= -1 x ($3.50 - $24.14) / $24.14
85.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Aratana Therapeutics is available for.
Intrinsic value
>50%
Share price is $3.5 vs Future cash flow value of $24.14
Current Discount Checks
For Aratana Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Aratana Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Aratana Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aratana Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aratana Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:PETX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.32
NasdaqGM:PETX Share Price ** NasdaqGM (2019-04-18) in USD $3.5
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.42x
United States of America Market PE Ratio Median Figure of 3,081 Publicly-Listed Companies 18.18x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aratana Therapeutics.

NasdaqGM:PETX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:PETX Share Price ÷ EPS (both in USD)

= 3.5 ÷ -0.32

-11.08x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aratana Therapeutics is loss making, we can't compare its value to the US Pharmaceuticals industry average.
  • Aratana Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Aratana Therapeutics's expected growth come at a high price?
Raw Data
NasdaqGM:PETX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -11.08x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
55.9%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 23 Publicly-Listed Pharmaceuticals Companies 1.5x
United States of America Market PEG Ratio Median Figure of 2,109 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aratana Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aratana Therapeutics's assets?
Raw Data
NasdaqGM:PETX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.10
NasdaqGM:PETX Share Price * NasdaqGM (2019-04-18) in USD $3.5
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 181 Publicly-Listed Pharmaceuticals Companies 3.44x
United States of America Market PB Ratio Median Figure of 5,184 Publicly-Listed Companies 1.91x
NasdaqGM:PETX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:PETX Share Price ÷ Book Value per Share (both in USD)

= 3.5 ÷ 2.10

1.67x

* Primary Listing of Aratana Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aratana Therapeutics is good value based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Aratana Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Aratana Therapeutics has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Aratana Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
55.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aratana Therapeutics expected to grow at an attractive rate?
  • Aratana Therapeutics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Aratana Therapeutics's earnings growth is expected to exceed the United States of America market average.
  • Aratana Therapeutics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:PETX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:PETX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts 55.9%
NasdaqGM:PETX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 26.6%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 18.7%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.4%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:PETX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:PETX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 129 38 2
2022-12-31 125 39 2
2021-12-31 92 17 13 3
2020-12-31 70 4 11 4
2019-12-31 35 -19 -17 4
NasdaqGM:PETX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 35 -11 -15
2018-09-30 41 -23 -22
2018-06-30 26 -28 -39
2018-03-31 26 -33 -43
2017-12-31 26 -38 -48
2017-09-30 15 -55 -55
2017-06-30 9 -65 -60
2017-03-31 42 -16 -28
2016-12-31 39 -11 -34
2016-09-30 38 -5 -23
2016-06-30 39 3 -64
2016-03-31 1 -43 -93

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aratana Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Aratana Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:PETX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Aratana Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:PETX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.71 0.81 0.61 2.00
2022-12-31 0.73 1.00 0.46 2.00
2021-12-31 0.26 0.28 0.22 3.00
2020-12-31 0.21 0.31 0.11 2.00
2019-12-31 -0.35 -0.29 -0.41 4.00
NasdaqGM:PETX Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.32
2018-09-30 -0.48
2018-06-30 -0.90
2018-03-31 -1.02
2017-12-31 -1.17
2017-09-30 -1.42
2017-06-30 -1.61
2017-03-31 -0.79
2016-12-31 -0.95
2016-09-30 -0.66
2016-06-30 -1.86
2016-03-31 -2.71

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Aratana Therapeutics is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Aratana Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aratana Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Aratana Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aratana Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aratana Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Aratana Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aratana Therapeutics's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Aratana Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aratana Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:PETX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 35.41 -14.72 28.78 6.86
2018-09-30 40.96 -21.69 28.99 8.84
2018-06-30 25.57 -39.44 28.89 10.55
2018-03-31 25.82 -43.45 29.10 12.68
2017-12-31 25.57 -47.51 28.90 15.13
2017-09-30 15.41 -55.25 29.04 20.65
2017-06-30 9.29 -59.69 29.06 22.76
2017-03-31 42.17 -28.12 28.29 24.37
2016-12-31 38.55 -33.58 27.34 30.46
2016-09-30 38.32 -23.10 25.38 27.85
2016-06-30 38.51 -64.17 23.45 28.71
2016-03-31 0.69 -93.35 22.19 29.49
2015-12-31 0.68 -84.05 21.07 24.96
2015-09-30 0.86 -81.46 20.47 24.53
2015-06-30 0.68 -37.14 19.58 24.42
2015-03-31 0.75 -38.44 19.03 22.63
2014-12-31 0.77 -38.82 17.87 19.99
2014-09-30 0.64 -24.09 15.90 17.06
2014-06-30 0.60 -18.64 13.22 14.21
2014-03-31 0.30 -12.02 10.15 12.38
2013-12-31 0.12 -6.94 6.90 10.93
2013-09-30 -16.15 4.71 9.77
2013-06-30 -14.64 4.35 8.19
2013-03-31 -15.05 3.72 7.65
2012-12-31 -13.67 2.99 7.29

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aratana Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aratana Therapeutics has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aratana Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aratana Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aratana Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Aratana Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aratana Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aratana Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aratana Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aratana Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Aratana Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aratana Therapeutics Company Filings, last reported 3 months ago.

NasdaqGM:PETX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 100.82 0.00 42.67
2018-09-30 108.40 25.24 56.02
2018-06-30 93.51 29.60 60.03
2018-03-31 95.64 33.97 66.93
2017-12-31 80.13 36.83 67.62
2017-09-30 93.73 36.85 70.34
2017-06-30 100.05 38.09 80.32
2017-03-31 81.06 40.31 68.02
2016-12-31 90.40 40.19 88.30
2016-09-30 111.23 40.07 102.34
2016-06-30 109.62 39.95 109.51
2016-03-31 86.92 39.83 72.81
2015-12-31 101.55 39.71 86.20
2015-09-30 112.97 14.98 72.77
2015-06-30 165.09 14.98 83.59
2015-03-31 171.50 14.97 87.41
2014-12-31 181.83 14.96 98.07
2014-09-30 193.01 14.96 108.26
2014-06-30 160.07 14.94 70.72
2014-03-31 169.11 14.94 79.94
2013-12-31 83.39 17.94 45.75
2013-09-30 43.84 4.94 52.31
2013-06-30 13.92 4.94 20.24
2013-03-31 17.25 4.93 25.65
2012-12-31 17.64 0.00 20.36
  • Aratana Therapeutics has no debt.
  • Aratana Therapeutics has no debt compared to 5 years ago when it was 21.2%.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aratana Therapeutics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Aratana Therapeutics has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 3.4% each year.
X
Financial health checks
We assess Aratana Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aratana Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Aratana Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aratana Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Aratana Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aratana Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aratana Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:PETX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2009 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:PETX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aratana Therapeutics has not reported any payouts.
  • Unable to verify if Aratana Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aratana Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aratana Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Aratana Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Aratana Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aratana Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aratana Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Aratana Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Craig Tooman
COMPENSATION $950,282
AGE 52
TENURE AS CEO 0.3 years
CEO Bio

Mr. Craig A. Tooman, MBA served as Chief Financial Officer and Treasurer at Aratana Therapeutics, Inc. since November 8, 2013 and January 2014 respectively until February 1, 2019. Mr. Tooman has been Chief Executive Officer, President and Board Director of Aratana Therapeutics, Inc. since January 17, 2019. He served as the Chief Executive Officer at Avanzar Medical, Inc since February 2012 until November 2014. He founded Stockbourne LLC and also serves as its Principal. He served as the Chief Financial Officer and Senior Vice President of Finance at Ikaria, Inc. from August 2010 to October 2011. He served as Executive Vice President of Finance and Chief Financial Officer of Enzon Pharmaceuticals Inc. from June 10, 2005 to July 23, 2010 and served as its Principal Accounting Officer until July 23, 2010. Mr. Tooman served as an Executive Vice President of Strategic Planning & Corporate Communications at Enzon Pharmaceuticals Inc., from January 2005 to June 10, 2005. Mr. Tooman joined ILEX in March 2002 as a Vice President of Investor Relations. Mr. Tooman served as Senior Vice President of Strategic Planning and Corporate Communications of Ilex Oncology Inc. since September 2002, which was acquired by Genzyme Corporation in December 2004. He has industry experience and has worked extensively in diverse pharmaceutical positions including, investor communications, strategic planning, finance, marketing and sales. While at Ilex, Mr. Tooman managed the formation of Ilex's first comprehensive strategic plan and the restructuring of Enzon Pharmaceuticals Inc., clinical development activities to drive transformation from a drug development contract research organization into a product-driven pharmaceutical company. Mr. Tooman was also charged with leading the integration of Ilex and Genzyme, a $1 billion transaction that maintained the majority of Ilex's operations. Before joining Ilex, Mr. Tooman worked at Pharmacia LLC where he progressed through positions of increasing responsibility in investor relations including Vice President of Investor Relations from 2000 to 2001. Prior to the merger of Pharmacia & Upjohn and Monsanto, he served as Assistant Vice President of Investor Relations for Pharmacia & Upjohn from 1999 to 2000 and as Worldwide Director of Investor Relations from 1998 to 1999. He served as a Director of Investor Relations, Europe and as a Director of Corporate Strategy for Pharmacia & Upjohn Management Co., from 1996 to 1997. In this role, he was responsible for global investor relations activities and spearheaded communications with the financial community on the Pharmacia and Upjohn/Monsanto merger. Additionally, under his leadership the Investor Relations unit of Pharmacia won four of the largest awards of distinction in Investor and Public Relations. Mr. Tooman has also held various management positions in Europe and Japan. He serves as a Director of Spindletop Capital. He has been a Director at Xanodyne Pharmaceuticals Inc. since October 2007. He served as Director of InSite Vision Incorporated from September 20, 2011 to November 2, 2015. He served as a Director of Pharmacia LLC and Aratana Therapeutics, Inc from April 2012 to November 8, 2013. He has been named Entrepreneur-in-Residence by the State of Texas and Cancer Prevention and Research Institute of Texas. Mr. Tooman received a Master of Business Administration degree in finance from the University of Chicago and a Bachelor of Arts degree in economics from Kalamazoo College.

CEO Compensation
  • Craig's compensation has increased whilst company is loss making.
  • Craig's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Aratana Therapeutics management team in years:

0.3
Average Tenure
46
Average Age
  • The average tenure for the Aratana Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Craig Tooman

TITLE
President
COMPENSATION
$950K
AGE
52
TENURE
0.3 yrs

Ernst Heinen

TITLE
Chief Development Officer
COMPENSATION
$802K
AGE
55
TENURE
6.8 yrs

Rhonda Hellums

TITLE
CFO & Treasurer
AGE
46
TENURE
0.2 yrs

John Ayres

TITLE
VP of Corporate Development and Administration
AGE
39
TENURE
0.3 yrs

Rachel Reiff

TITLE
Head of Corporate Communications

Chris Ready

TITLE
VP of Sales & Marketing
AGE
44
TENURE
0.4 yrs
Board of Directors Tenure

Average tenure and age of the Aratana Therapeutics board of directors in years:

4.7
Average Tenure
62
Average Age
  • The tenure for the Aratana Therapeutics board of directors is about average.
Board of Directors

Wendy Yarno

TITLE
Chairperson
COMPENSATION
$129K
AGE
63
TENURE
3.7 yrs

Craig Tooman

TITLE
President
COMPENSATION
$950K
AGE
52
TENURE
0.3 yrs

John Vander Vort

TITLE
Director
COMPENSATION
$107K
AGE
53
TENURE
6.6 yrs

Bob Roche

TITLE
Director
COMPENSATION
$109K
AGE
62
TENURE
4.8 yrs

Lowell Robinson

TITLE
Director
AGE
69
TENURE
0.9 yrs

Merilee Raines

TITLE
Director
COMPENSATION
$107K
AGE
62
TENURE
5.2 yrs

David Brinkley

TITLE
Director
COMPENSATION
$112K
AGE
61
TENURE
5.1 yrs

Irv Hockaday

TITLE
Director
COMPENSATION
$103K
AGE
82
TENURE
4.7 yrs

Craig Barbarosh

TITLE
Director
AGE
50
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
10. Jan 19 Sell Engaged Capital, LLC Company 09. Nov 18 08. Jan 19 -2,123,153 $6.81 $-14,465,891
20. Aug 18 Buy Engaged Capital, LLC Company 08. Aug 18 20. Aug 18 632,099 $5.19 $3,207,702
07. Aug 18 Buy Engaged Capital, LLC Company 31. Jul 18 07. Aug 18 842,312 $4.98 $3,796,020
X
Management checks
We assess Aratana Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aratana Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Kind Of Shareholders Own Aratana Therapeutics, Inc. (NASDAQ:PETX)?

Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … Companies that have been privatized tend to have low insider ownership. … Taking a look at our data on the ownership groups (below), it's seems that.

Simply Wall St -

Does Aratana Therapeutics, Inc. (NASDAQ:PETX) Have A Volatile Share Price?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

The Aratana Therapeutics Share Price Is Down 79% So Some Shareholders Are Rather Upset

Given that Aratana Therapeutics didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. … Shareholders of unprofitable companies usually expect strong revenue growth. … In the last half decade, Aratana Therapeutics saw its revenue increase by 55% per year.

Simply Wall St -

Aratana Therapeutics, Inc. (NASDAQ:PETX): Commentary On Fundamentals

Want to participate in a short research study? … Help shape the future of investing tools and you could win a $250 gift card! … Attractive stocks have exceptional fundamentals.

Simply Wall St -

Aratana Therapeutics, Inc. (NASDAQ:PETX): Time For A Financial Health Check

(NASDAQ:PETX) is a small-cap stock with a market capitalization of US$215m. … While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Assessing first and foremost the financial health is

Simply Wall St -

How Much Of Aratana Therapeutics, Inc. (NASDAQ:PETX) Do Institutions Own?

Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Aratana Therapeutics is not a large company by global standards. … institutions own shares in the company.

Simply Wall St -

Aratana Therapeutics Inc (NASDAQ:PETX): Are Analysts Optimistic?

Aratana Therapeutics Inc's (NASDAQ:PETX):. … Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. … The US$321m market-cap posted a loss in its most recent financial year of -US$47.5m and a latest trailing-twelve-month loss of -US$21.7m shrinking the gap between loss and breakeven.

Simply Wall St -

Does Aratana Therapeutics Inc (NASDAQ:PETX) Have A Particularly Volatile Share Price?

Modern finance theory considers volatility to be a measure of risk, and there are two main types of price volatility. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … While we should keep in mind that Warren Buffett has cautioned that 'Volatility is far from synonymous with risk', beta is still a useful factor to consider.

Simply Wall St -

Should You Worry About Aratana Therapeutics Inc's (NASDAQ:PETX) CEO Pay Check?

First, this article will compare CEO compensation with compensation at similar sized companies. … Peter's Compensation Compare With Similar Sized Companies. … Our data indicates that Aratana Therapeutics Inc is worth US$272m, and total annual CEO compensation is US$3m.

Simply Wall St -

Is Aratana Therapeutics Inc's (NASDAQ:PETX) Balance Sheet A Threat To Its Future?

Investors are always looking for growth in small-cap stocks like Aratana Therapeutics Inc (NASDAQ:PETX), with a market cap of US$239.31m. … However, an important fact which most ignore is: how financially healthy is the business? … Evaluating financial health as part of your investment thesis is

Simply Wall St -

Company Info

Description

Aratana Therapeutics, Inc., a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States. Its product portfolio includes small molecule therapeutics and therapeutic candidates. The company markets NOCITA, a post-operative analgesia for cranial cruciate ligament surgery in dogs; ENTYCE for appetite stimulation in dogs; GALLIPRANT for the control of pain and inflammation associated with osteoarthritis in dogs; and canine osteosarcoma vaccine, live listeria vector for the treatment of dogs diagnosed with osteosarcoma in the United States. It is also developing NOCITA, a bupivacaine liposome injectable suspension for post-operative pain in cats; AT-002, a specific formulation of capromorelin for use in cats; AT-018, an oral CRTH2 antagonist for the treatment of atopic dermatitis in dogs; AT-006, an anti-viral eprociclovir that is used for the treatment of feline herpes virus-induced ophthalmic conditions in cats; AT-016, allogeneic adipose-derived stem cells for dogs; and AT-019, an EP4 receptor antagonist therapeutic candidate with potential in pain, inflammation, and other indications. In addition, the company develops AT-008, a therapeutic candidate for treating canine lymphoma in dogs; and other therapeutics for dogs and cats in Europe. It has collaboration agreement with Elanco Animal Health, Inc. to develop, manufacture, and commercialize GRAPIPRANT products; Pacira Pharmaceuticals, Inc. to develop and commercialization of licensed animal health products for NOCITA; and AskAt Inc for the development and commercialization of compound AT-019. Aratana Therapeutics, Inc. was founded in 2010 and is headquartered in Leawood, Kansas.

Details
Name: Aratana Therapeutics, Inc.
PETX
Exchange: NasdaqGM
Founded: 2010
$171,409,798
48,974,228
Website: http://www.aratana.com
Address: Aratana Therapeutics, Inc.
11400 Tomahawk Creek Parkway,
Suite 340,
Leawood,
Kansas, 66211,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM PETX Common Stock Nasdaq Global Market US USD 27. Jun 2013
DB AT5 Common Stock Deutsche Boerse AG DE EUR 27. Jun 2013
Number of employees
Current staff
Staff numbers
83
Aratana Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/22 00:26
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/17
Last earnings filing: 2019/03/13
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.